Sinerga has developed an anti-aging peptide, ATP 23 (INCI: Azeloyl Tetrapetide-23), to reduce oxidative damage and inhibit the glycation of dermal proteins. According to the company, skin aging is a natural phenomena that results from the depolymerization of the dermis matrix, resulting in the slow deterioration of tissue function, turgidity of the skin, wrinkles and stretch marks. This process is accelerated by free radicals from environmental sources, mainly UV radiation. The ingredient was therefore designed to address these symptoms of aging.
The product is constituted by a lipophilic carrier to enhance its antioxidant activity, which is intended to inhibit the production of Advanced Glycation End products (AGEs) in dermal proteins and to renew skin cells. In vitro testing confirmed the product reduced antioxidant activity by 60%, inhibited the formation of AGEs in human fibroblasts by up to 50%, and reduced free radical scavenging activity by 40%.
Further, photo-imaging analysis revealed as 10% clinical reduction of profilometric parameters; i.e., wrinkles appeared less evident and deep. According to the company, the product also showed a general tendency to enhance skin elasticity, density and brightness.